Mauna Kea Technologies (STU:1MK) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1MK Mauna Kea Technologies SA STU:1MK
47 GF Score
Price €0.15
GF Value €0.11
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Mauna Kea Technologies FFO?

FFO (Funds from operations) only applies to REITs.

STU:1MK
47GF Score
Mauna Kea Technologies SA STU:1MK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mauna Kea Technologies (STU:1MK) Overvalued in 2026?

Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued. The current stock price of €0.15 is trading 34.9% above its estimated GF Value™ of €0.11. GuruFocus considers Mauna Kea Technologies to be Significantly Overvalued.

Key valuation signals for STU:1MK:

  • FFO:
  • GF Value™: €0.11 vs. price of €0.15 (34.9% above fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the STU:1MK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mauna Kea Technologies Business Description

Address 9 rue d\'Enghien, Paris, FRA, 75010
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
47GF Score

Get the complete analysis for STU:1MK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.11
GF Value